Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.73 |
| ▸ | MTOR | P42345 | 7/20 | 0.60 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.59 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | PRKACG | P22612 | 1/20 | 0.59 |
| ▸ | PRKACB | P22694 | 1/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1311366 | 0.92 | PIK3CA (0.73) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1308900 | 0.89 | PIK3CA (0.75) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1309662 | 0.86 | PIK3CA (0.55) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1309501 | 0.86 | PIK3CA (0.55) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1310195 | 0.86 | PIK3CA (0.55) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1310024 | 0.86 | PIK3CA (0.55) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1310378 | 0.86 | PIK3CA (0.55) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1310660 | 0.86 | PIK3CA (0.57) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1310662 | 0.86 | PIK3CA (0.57) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL960078 | 0.84 | PIK3CA (1.00) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | claimed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | claimed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.